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This research explores a possible benefit to chronic fatigue syndrome and myalgic 
encephalomyelitis (ME/CFS) sufferers with the use of low-dose beta blockers as previous 
studies show potential for these treatments to lessen the symptoms of pain and fatigue in 
ME/CFS. Clinical data were collected from 55 patients treated with beta-adrenergic 
receptor-blocking agents, primarily propranolol, at the Fatigue Consultation Clinic run by 
Dr. Lucinda Bateman. Patient data were collected before and during treatment with the 
beta-blocking agents, and statistical analysis identified correlations between treatment 
and changes in reported measures of fatigue, body aches, pain, headaches, 
inactivity/function, hours spent vertical in a 24 hour period, and hours spent horizontal in 
a 24 hour period. After performing statistical analysis on the data, no correlations 
between the treatment and symptom severity were apparent. However, the subjective 
nature of the clinical data and the potential for confounding variables warrant a more 
complete clinical trial. 
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 LITERATURE REVIEW  
 
Myalgic encephalomyelitis (ME) or chronic fatigue syndrome (CFS) is a complex 
and debilitating neurological disease affecting multiple biological systems including the 
immune, endocrine, cardiovascular, and central nervous systems, and aspects of energy 
metabolism. This constellation of multisystem complications synergistically wreaks 
havoc on the life of affected individuals. Most patients are no longer able to work, carry 
on social activities, perform daily activities such as feeding themselves or, in some cases, 
even get out of bed. ME/CFS can strike anyone at any time, without regard to 
socioeconomic status or ethnicity.
1
 ME/CFS also seems to increase a person’s risk of 
suicide as well as certain types of cancer.
2,3
 An estimated one to five million Americans 
suffer from the condition and the globally estimated prevalence is 0.4-1%.
1,4
 Although 
being female makes a person six times more likely to get ME/CFS, both men and women, 
old and young, are afflicted.
1,4
 Children and adolescents are affected at a similar rate as 
adults, but have higher rates of recovery than their older counterparts.
1,4
 This condition is 
poorly understood, but millions are desperate for researchers and the medical community 
to solve the ME/CFS puzzle so sufferers can regain their quality of life.  
What causes ME/CFS is still unknown, but research continues as funding allows. A 
separate theory of the etiology of ME/CFS likely exists for every different researcher. 
2 
 
The medical field is rife with confusion and debate over the various aspects of the illness. 
One side of the spectrum hypothesizes a biological cause, while the other end postulates a 
purely psychological etiology of ME/CFS. The truth probably lies somewhere in the 
middle, but currently, people are left trying to overcome the differences of opinion that 
abound surrounding the root cause of ME/CFS. 
Diagnosis of ME/CFS is perhaps as challenging as identifying a cause. Multiple tests 
or criteria have been recommended, but a clear cut pathognomonic tool for diagnosis is 
still lacking. As difficult as accurately diagnosing ME/CFS is, finding a way to treat or 
possibly cure sufferers far surpasses that challenge. Countless treatment options have 
been explored both anecdotally and in controlled clinical trials, but very few have shown 
any reproducible efficacy. Many patients explore mainstream medical treatment options 
only to turn away with disappointment and seek out alternative options when the former 
fails them. The relationship between provider and patient is often tenuous as 
disagreements arise over what the root cause is or what the best approach to treatment 
may be. Despite all these issues regarding ME/CFS, one thing can be agreed upon: this 
condition is devastating to all aspects of a person’s life.  
 
1.1 History 
     ME/CFS remains unexplained to date, but research continues to add understanding to 
its pathogenesis. In 1869 the first publication referencing a condition thought to be  
ME/CFS identified a disease state called neurasthenia or nervous exhaustion with 
symptoms including fatigue, headache, impotence, neuralgia, anxiety, and depression.
5
 
Then in 1904 Angelo Mosso published a landmark manuscript researching the nature of 
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fatigue that has, to this day, influenced the way fatigue is understood and studied.
6
 The 
evolution of neurasthenia and fatigue continued when in 1938, during the polio epidemic, 
Alexander Gilliam identified what he called atypical poliomyelitis with symptoms of 
muscle weakness, clonic twitches and cramps, vasomotor instability, ataxia, severe pain 
aggravated by exercise, neck and back stiffness, menstrual disturbance and dominant 
sensory involvement.
7
 In 1955 the term myalgic encephalomyelitis (ME) was coined for 
the condition after an outbreak at a hospital in London
8
. Although these historical cases 
may not have been what is classified as ME/CFS today, the unique description of the 
symptomatology in many of the cases strikes an unquestionable resemblance to the 
current definition of ME/CFS. The name ME remains in use today in much of the world 
and is often interchangeable with the term CFS. In 1978 the Royal Society of Medicine 
published a paper describing the symptoms of ME as objective and biological in nature.
9
 
Since then, the definition and description of the condition has been refined, but 
researchers remain undecided as to the true nature of ME/CFS.
10
 Currently the World 
Health Organization (WHO) classifies ME as a neurological disease under the 
International Statistical Classification of Diseases and Related Health Problems 10th 
Revision.
11
 However, the United States Centers for Disease Control and Prevention 
(CDC) has not adopted the name ME, but instead uses the name CFS. The CDC 
definition, as seen in Figure 1, focuses more on subjective and somatoform symptoms 
and puts emphasis on a diagnosis of exclusion of other conditions while the WHO 
definition focuses more on biological symptoms and has specific criteria that must be met 








The CDC case definition of ME/CFS 
 Had six or more months of consecutive fatigue that is not relieved by  
sufficient bed rest and is not caused by another underlying medical condition. 
 The fatigue significantly interferes with daily activities and work.  
 The individual concurrently has four or more of the following eight symptoms: 
o Postexertion malaise lasting more than 24 hours 
o Unrefreshing sleep 
o Significant impairment of short-term memory or concentration 
o Muscle pain 
o Multijoint pain without swelling or redness 
o Headaches of a new type, pattern, or severity 
o Tender cervical or axillary lymph nodes. 
o A sore throat that is frequent or recurring. 
 
Figure 1. Diagnostic criteria and ME/CFS case definition of the CDC. 









     These differences in definition lead to confusion and ambiguity for researchers, 
patients, and the media. Only recently in peer reviewed literature have the two terms been 
combined as ME/CFS, even though the two names describe the same disease state. The 
first major U.S. journal article published using the sole title myalgic encephalomyelitis to 
reference the condition was as recent as 2011 in the Journal of Internal Medicine.
12
 
Before that, only the titles CFS or CFS/ME appeared in major U.S. publications. Even 
though the WHO classifies ME/CFS as a disease of the nervous system, many healthcare 
professionals view it as a psychologically based somatic syndrome with no organic 
origin. This conflict of opinion has divided the ME/CFS researchers into different camps 
that tend to focus their research toward their own bias and further obscure the ME/CFS 
picture.
13
 As research advances, the current understanding of ME/CFS will become 
clearer and help for these individuals will increase. 
 
1.2 Clinical Presentation 
In almost every case, ME/CFS begins with a specific stressor, often a viral infection, 
but can be anything from an auto accident to the death of a loved one.
4
 The onset is 
usually acute and most patients can cite almost to the day when their illness began.
12,14
 
The initial complaints frequently include fever, lymphadenopathy, abdominal pain, and 
digestive discomfort as well as nervousness and anxiety about the symptoms, especially 
as the medical professionals fail to provide an explanation for the symptoms. After a 
short period of time, fatigue and myalgia become the prominent complaints with 
particular emphasis on the unique nature of the fatigue that usually appears roughly a day 
after any physical or mental exertion and lasts for days or weeks.
13
 Many people who 
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have experienced ME/CFS find difficulty in describing the nature of the pain and fatigue 
associated with the condition, but others have described it as postexertional malaise that 
occurs 24 to 48 hours after physical or mental activity. Sufferers often say this 
understates the symptoms. The fatigue debilitates and often leaves the patient unable to 
walk, stand, or even sit upright following activity, similar to having a dead battery. Some 
of the more common symptoms documented are impaired mental function and short-term 
memory difficulties, unrefreshing sleep, migratory arthralgia, unusual headaches, sore 
throat, chills or sweating, chest pain, visual disturbances, food, drug, or chemical 
sensitivities, light and temperature sensitivities, orthostatic intolerance (OI), dizziness, 
loss of balance and coordination, depression, anxiety, moodiness, and menstrual changes 
in women.
9-20
 All these symptoms become exacerbated with physical or mental exertion. 
The frequency and severity to which these symptoms occur differs widely from one 
individual to another, but the unique fatigue and postexertional malaise is found in every 
case of ME/CFS and only found in ME/CFS sufferers.
12
 This chronic and persistent 
combination of symptoms paints a dismal picture for the sufferer. Complete disability is 
common. Many patients lack the mental capacity or social support to attain help and 
consequently become isolated, bed bound, and hopeless, with poor quality of life. Many 
patient support organizations actively search for an explanation to the cause, or at least a 
laboratory test that could accurately diagnose the condition, to dispel much of the 
confusion and controversy that surround it, but for now ME/CFS remains a diagnosis of 
exclusion, and the research pools are muddied with patients who may not actually fit the 





Currently, a diagnosis that cannot be made with a positive laboratory test or well 
defined clinical signs and symptoms must be made by exclusion of all other possibilities. 
In the United States the most commonly used diagnostic criteria comes from the CDC 
and was originally proposed by Fukuda and his colleagues.
14
 Under these criteria, a 
diagnosis of ME/CFS is made if a patient meets the criteria listed in Figure 1. 
These criteria capture most cases of ME/CFS, but critics say that by following the 
CDC criteria, many people who do not have ME/CFS may be falsely diagnosed. The 
inclusion of confounding conditions makes progress in ME/CFS research difficult. 
Everything from sleep disorders to HIV-AIDS to depression have been placed under the 
ME/CFS umbrella.
22,23
   
In 2011 a group of researchers put together a new diagnostic criteria called the 
International Consensus Criteria (ICC) (See Appendix A), but it has yet to be adopted 
widely by the international communities and the United States.
12
 The ICC, if adopted, 
would help remove many of the confounding conditions from research studies because it 
follows narrow and specific diagnostic guidelines, including compulsory postexertional 
neuroimmune exhaustion, neurological impairments, immune, gastro-intestinal and 
genitourinary impairments, and energy production or transportation impairments 
symptoms. Although not officially used in the USA, many researchers base their research 




Much of the research on ME/CFS has historically focused on one or more specific 
symptoms, but identifying a root cause remains the ultimate goal of many researchers. 
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Some of the more promising and investigated theories are a single infectious agent, a 
hormonal imbalance, neurological abnormalities, immune system dysfunction, 
mitochondrial dysfunction, genetic predisposition or abnormalities, or a complex 
combination of these etiologies.  
The theory that a single infectious agent causes ME/CFS is most popular in the media 
and likely the most investigated potential cause. This is for good reason too, as many of 
the early onset symptoms of the condition resemble other infectious processes. A 
recurring, relapsing pattern of fever, tender lymph nodes, gastrointestinal distress, 
fatigue, and myalgia are commonly found in many viral or bacterial infections. From 
early in the history of the illness, infectious agents were considered. One theory 
suggested that the polio virus caused CFS/ME, but no virus was found, thus the name 
atypical polio was given.
7
 Another theory suggests that ME/CFS is a chronic form of 
Lyme’s disease caused by Borrelia burgdorferi.25 Epstein-Barr virus has been implicated 
and shown some clinical evidence of an association with ME/CFS, but the nature of that 
association has not been identified.
26
 Human herpes viruses 6 and 7 have also been 
explored with no causal link.
27,28
 Human retroviruses including human T-cell 
lymphotropic virus II (HTLV-II), JHK virus (JHKV), and xenotropic murine leukemia 
virus-related virus (XMRV) have brought the ME/CFS community to the edge of its 
collective seat, but no identifiable link has been found between the viruses and the 
condition.
29,30
 Coxsackievirus, cytomegalovirus, mycoplasma, and various fungal 
theories have arisen, been researched and then been pushed aside over the years.
4,31
 
Indeed, it seems the investigative world targets a new pathogen every few years, but 
repeatedly, the research ends with no more than a handful of questions and some weak 
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links between the organism in question and ME/CFS. It may be that the root cause of the 
condition begins with a change in the nervous or immune system that leads to increased 
risk of infectious processes, or perhaps multiple pathogens are capable of triggering a 
common pathway. 
ME/CFS appears even more complex when investigating the hormonal imbalances of 
the condition. The hypothalamo-pituitary-adrenal (HPA) axis has been blamed for many 
of the symptoms of ME/CFS, and it may yet prove to be an important factor, but once 
again, the HPA axis does not seem to be the root cause of the condition, but merely a 
secondary complication. Patients show dysregulation of different hormones at various 
times throughout the illness.
32,33
 At the onset of being sick, a person usually has some 
kind of physical, emotional, or mental stressor that triggers an increase in cortisol and 
cortisol releasing hormone (CRH) levels. This hormone increase upregulates the immune 
system and other body systems in healthy controls and ME/CFS sufferers alike, but 
studies demonstrate a significant decrease in cortisol and CRH levels of ME/CFS patients 
when compared to control groups. This depressed cortisol response seen in ME/CFS 
sufferers still falls within the clinically normal range and is therefore not detected by 
many clinicians. Despite significant differences in these patients, cortisol cannot be used 
as an ME/CFS biomarker. Other studies show that cortisol replacement does not 
significantly benefit the ME/CFS patient. Other hormonal imbalances are also common in 
ME/CFS patients. Growth hormone, leptin, and melatonin have been implicated and 
found to have subtle abnormalities in the patient population; however, like all other 
avenues explored to date, these are not significant or reproducible enough as a diagnostic 





Investigators of the neurological symptoms found in ME/CFS have identified 
abnormalities with functional magnetic resonance imaging (fMRI) and single-photon 
emission computed tomography (SPECT) scanning, but cannot show that these tests are 
specific or sensitive enough for diagnosis.
35,36
 Research continues into the neurological 
basis of the condition and as greater understanding into how the integrity and 
functionality of the neurological system impacts the body, a clearer understanding of the 
symptoms unique to ME/CFS may emerge. Current research is looking for potential 
neurological biomarkers for ME/CFS such as neuropeptide Y (NPY). NPY is a stress 
mediator found in the central and peripheral nervous system. Plasma levels of the stress 
induced peptide increase in times of systemic illnesses such as systemic lupus 
erythematosus and rheumatoid arthritis. A study looking for potential ME/CFS 
biomarkers demonstrated that NPY is significantly elevated in ME/CFS sufferers 
compared to controls showing an altered stress response in this population.
37
 The study 
correlates with others by implicating the HPA axis as a major component of ME/CFS  
The published literature also shows that the immune system is a major player in 
ME/CFS. Natural killer (NK) cells and cytokines have reduced function in patients with 
ME/CFS. Specifically, NK cells have deficiencies in perforin and granzymes and appear 
to be reduced in number.
38
 Cytokine profiles seem abnormal in ME/CFS patients with a 
tendency toward the proinflammatory response as well as an elevated number of 
lymphocytes expressing dipeptidyl peptidase IV (DPPIV). The measurement of NK 
activity along with DPPIV expression on the lymphocytes are  predictable markers in 
identifying patients with ME/CFS, but more work is necessary to show reproducibility 





Another advancement in developing a functional diagnostic tool for ME/CFS is 
mitochondrial function testing. A group of researchers have shown that ATP production 
and mitochondrial function in ME/CFS patients is significantly reduced compared with 
the control group. They have also shown that the severity of the patient’s condition 
correlates to the dysfunction of the mitochondrial function and energy production.
40
 The 
researchers are not clear on whether the mitochondrial dysfunctions are the primary cause 
of the condition or just a secondary effect of an upstream problem, but mitochondrial 
dysfunction relates to many symptoms suffered by ME/CFS patients as well as people 
suffering with other chronic conditions with similar symptoms.
40 
While research continues on chemical and microbiological methods of diagnosis, 
more promising methodologies using molecular methods and advanced genetic modeling 
studies to identify individuals who may be genetically predisposed with increased risk of 
ME/CFS and other diseases may be more fruitful. A recent study found nine genes using 
microarray and quantitative polymerase chain reaction (qPCR) methods that are strongly 
associated with ME/CFS. The genes identified, STAT5A, PSMA4, PSMA3, HINT1, 
DBI, COX5B, ATP5J2, GZMA, and RHOC, associate with various aspects of the 
immune system, cellular transport, or receptor/binder interactions.
41
 This study was 
limited in scope, but further studies are underway to identify more correlations between 
these genes and symptoms of ME/CFS. Another study found seven genomic subtypes of 
ME/CFS and related the genotypes to different phenotypes. The genetic profiles formed 
using clustering of qPCR data revealed these clinical subtypes: subtype 1 (cognitive, 
musculoskeletal, sleep, anxiety/depression); subtype 2 (musculoskeletal, pain, 
anxiety/depression); subtype 3 (mild); subtype 4 (cognitive); subtype 5 (musculoskeletal, 
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gastrointestinal); subtype 6 (postexertional); subtype 7 (pain, infectious, musculoskeletal, 
sleep, neurological, gastrointestinal, neurocognitive, anxiety/depression).
42
 These 
subtypes may prove useful in further isolating patient populations for research and 
treatment purposes. A third study, published by researchers at the University of Utah, 
investigated the gene expression of ME/CFS patients after exertion. This study found 
significant results offering a possible explanation for the postexertional fatigue and 
malaise experienced in ME/CFS. Thirteen genes were studied using mRNA extracted and 
measured by qPCR. The study identified four classes of severity in the patient population 
with matching control groups. The gene expression of each of the genes, ASIC3, P2RX4, 
P2RX5, TRPV1, ADRA2A, ADRB1, ADRB2, COMT, IL6, IL10, LTA, TLR4, and 
CD14 is shown in Figure 2.
43
 The study demonstrated a positive correlation between the 
severity of the symptoms a patient experiences and the increased expression of the 
selected genes. Isolating only a few of these genes, P2RX4, LTA, ADRB2, and IL10, as 
biomarkers after moderate exercise yielded a sensitivity of 0.93 and a specificity of 0.77 
with an accuracy of 0.80.
43
 These indicators show that these tests are potentially effective 
diagnostic biomarkers for ME/CFS, but work remains to show reproducibility and to 
further isolate subtypes based on gene expression patterns. Another finding in the gene 
expression studies is that the genes under investigation typically are not expressed during 
times of viral infection, but may lead to increased risk of acquiring a viral infection. This 
may explain the confounding influence pathogens have had since the start of the ME/CFS 












Figure 2. Histogram of genetic expression of sixteen genes associated with ME/CFS 
grouped in four classes of symptom severity in ME/CFS patients. 
(Data Source: Light AR, Bateman L, Jo D, Hughen RW, Vanhaitsma TA, White AT, 
Light KC: Gene expression alterations at baseline and following moderate exercise in 





studies show significant deviation from the normal population in ME/CFS patients.
32
 
Researchers at the CDC identified single nucleotide polymorphisms in the glucocorticoid 
receptor gene (NR3C1) as having a strong correlation with ME/CFS patients. These 
studies showed that the NR3C1 gene was affected by gene-environment interactions and 
attempted to explain part of the etiology of ME/CFS as regulated by environmentally 
influenced changes in NR3C1 gene expression.
45
 The changes in this gene, along with 
other receptor genes, are enlightening the ME/CFS pathophysiology and may explain the 
HPA involvement in the condition, but that is only part of the clinical picture. 
 
1.4 Treatment 
The prognosis for ME/CFS is bleak at best. Although the condition does not 
significantly increase mortality, the quality of life for the sufferers is so poor that suicide 
is one of the three leading causes of death, following heart disease and cancer.
22
 Due to 
the unclear etiology and no known and testable biomarkers for ME/CFS, current 
treatments tend to focus on alleviating symptoms rather that addressing the root cause of 
the illness. Two major schools of thought exist regarding treatment; those who believe 
ME/CFS is psychologically based and those who believe ME/CFS is biologically based.  
Psychologically based researchers gravitate towards treatments such as cognitive 
behavioral therapy (CBT) that attempts to reshape the way a patient views themselves 
and the illness that they are living with. CBT improves the quality of life of ME/CFS 
sufferers according to peer reviewed studies.
46
 However, this does not prove or disprove 
the psychosomatic hypotheses as other organically based conditions, such as multiple 
sclerosis and ovarian cancer, are also helped by CBT.
47,48
 CBT can help people learn to 
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deal with the daily challenge posed by any chronic condition, including ME/CFS, and 
play an important role in alleviating suffering and helping these people regain some 
functionality.  
Pacing of daily activities and stress reduction are another psychologically based way 
to cope with the chronic condition of ME/CFS and shows reduction in symptoms in many 
patients. The concept involves changing one’s life to match the energy capacity of one’s 
body and practicing biofeedback and stress reducing activities such as yoga, breathing 
exercises and meditation. If patients learn to reduce stress and avoid exceeding their 
energy expenditure threshold, they can avoid symptom flares. These techniques can 
improve the quality of life of the ME/CFS sufferer, but oftentimes drastic reductions in 
work, family, and social activities must be made to stay below a person’s energy 
expenditure threshold and remove the stresses of daily living.
49
 
Another treatment strategy that shows some validity in clinical trials is graded 
exercise therapy (GET). GET protocol asks the patient to gradually increase volume and 
intensity of exercises they do over an extended period of time trying not to exceed their 
energy limit and trigger a symptom flare. A patient may start out by walking from the bed 
to the couch one day and the next day they may do that same activity twice. Eventually, 
some patients demonstrate marked improvement in their exercise capacity and can even 
return to most activities of daily living. However, most patients do not make significant 
gains with GET, and it rarely significantly alleviates a patient’s symptoms over time.50 
Along with activity modifying treatment strategies, pharmaceutical treatments also 
abound. Many patients are in chronic pain, develop depression or anxiety secondary to 
their ME/CFS, and have difficulty sleeping. As a result, many different pharmaceuticals 
16 
 
target these symptoms with some success. Selective serotonin reuptake inhibitors, 
serotonin-norepinephrine reuptake inhibitors, sleep aids, anxiolytics, and other pain 
medications help alleviate these specific symptoms or comorbidities of ME/CFS. Other 
alternative treatment protocols such as naturopathic or dietary supplementation have not 
proven universally acceptable for the treatment of ME/CFS, although many patients use 
them and claim to benefit from them.
49,51
 
One promising pharmaceutical treatment option is the use of low-dose beta blockers 
to help patients have more energy, less pain, and potentially spend more time upright and 
active. Beta-adrenergic antagonists function through nonselective binding to the beta 
receptors primarily found on smooth muscle tissues of the heart, airways, arteries, 
kidneys and other tissues of the sympathetic nervous system. The blockade inhibits the 
binding of the catecholamines epinephrine and norepinephrine, blocking the effects of 
these stress hormones that include increased heart rate, blood pressure, blood glucose 
levels, and the general upregulation of the sympathetic nervous system. This general 
function of inhibiting the stress response leads to a number of medical uses for beta 
blockers including treatment of essential tremor, migraine, hypertropic subaortic stenosis, 
mitral valve prolapse, myocardial infarction, pheochromocytoma, atrial fibrillation, 
congestive heart failure, performance anxiety, and postural orthostatic tachycardia 
syndrome (POTS).
52-56
 Propranolol is administered orally and is lipophilic with high 
absorbance rates. ( Data Source: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid 
=c5091cd2-81c8-4ffe-b2aa-d053de5d6e12, last accessed October 8, 2014) The typical 
propranolol dose for the aforementioned conditions ranges from 80mg to up to 240mg 
daily. Previous studies show that doses closer to 40mg daily may be effective at 
17 
 
alleviating pain in some chronic pain conditions.
55
 Additionally, higher doses may lead to 
premature fatigue, which is one of the cardinal symptoms of ME/CFS.
57
  
Although none of these treatments cure ME/CFS, some individuals have shown long-
term remission using a combination of approaches. Part of the challenge of treating a 
condition such as this is that there is no clear cause to target. It is very likely that as 
research continues, several different causes will emerge that all lead to the same 
manifestation of symptoms. Only then will a treatment strategy truly target the root 








2.1 Introduction to Methods 
The aim of this study is to test the hypothesis that low-dose beta blockers are 
effective at improving symptoms of ME/CFS sufferers. This theory has been tested by 
other studies that show how low-dose propranolol can help reduce fatigue and pain.
57
 The 
present study builds on previous work by gathering historical clinical data from the 
Fatigue Consultation Clinic run by Dr. Lucinda Bateman. The patients were selected that 
have been treated with low-dose beta blockers to examine the effects, whether positive or 
negative, on their symptoms and identify any correlations between the treatment and 
symptom improvement. This pilot-study approach to research is an effective way to take 
a snapshot of the situation without expending exorbitant resources, but is limited in its 
ability to control for variables that exist in historical clinical data. 
 
2.2 Subjects 
Patients of Dr. Lucinda Bateman at the Fatigue Consultation Clinic in Salt Lake City, 
Utah were selected for inclusion in this study based on a review of medical records. Dr. 
Bateman has been using low-dose beta blockade for treatment of POTS and OI symptoms 
as well as pain and fatigue associated with ME/CFS for several years and has an 
19 
accessible database of patient records for this study. The electronic files at the clinic were 
retrospectively term-searched for propranolol and metoprolol. Any individual who had 
used these medications or had been counseled to try them as a treatment modality were 
included in the preliminary data analysis. Additionally, Dr. Bateman assisted in manual 
identification of patients not found in the electronic records search who were treated with 
beta blockers. Each patient selected met the ICC diagnostic criteria for CFS.
 
The date 
range for the data collected began on 3/23/05 and ended on 5/13/13. A total of 55 patient 
matches met the search criteria and were included in the study.  
  
2.3 Data 
The Fatigue Consultation Clinic uses an intake questionnaire (see Appendix B) that 
assesses patient symptoms on each visit. These self-evaluations were used to score each 
patient in categories of fatigue, body aches, pain, headaches, inactivity/function, hours 
spent vertical in a 24 hour period, and hours spent horizontal in a 24 hour period for each 
patient on each visit date. The scale for each question ranged from one to ten with one 
being the least severe symptoms and ten being the most severe. The questionnaire was 
changed in March of 2011 with the removal of the question for inactivity/function and the 
addition of the question for number of hours spent vertical and number of hours spent 
horizontal. These two questions were not scaled on a one to ten scale but were recorded 
in hours spent in each activity. The data prior to the change was converted to the 24 hour 
scale by using 17 hours as the maximum time a person would spend vertical and 
converting the one to ten scores to a 24 hour scale. The variables were then combined to 
create one variable from the inactivity/function variable and the hours spent vertical 
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variable. Two questions were listed for pain: body aches and pain. These scores were 
combined and averaged into one pain score for each visit date in an effort to measure 
overall pain. The individual pain questions of body aches and pain were also left 
separated in the analysis. Demographic data, dates of visits, and medication information 
were also collected from the questionnaires for each visit. Data from all clinic visit dates 
during beta blocker treatment were collected as well as up to three visit dates prior to the 
beginning of treatment, when available. The data were compiled in a spreadsheet and 
analyzed in RStudio for correlations between beta blocker treatment and symptom 
severity. Subjective comments related to propranolol or metoprolol treatment from 




A total of 156 visits were recorded for the 55 patients and all visits were included in 
the analysis. Using R and RStudio, the data were compiled and analyzed for statistical 
correlations. Graphical representation with boxplots of the data were created using the 
ggplot package to visualize any relationships within each variable between the before and 
after measures (see Appendix C). Following this step, scatterplots were made between 
each variable to identify any relationships between the variables and changes caused 
before or after beta blocker treatment (see Appendix D). Following graphical exploration 
of the relationships between all variables in the dataset, statistical analysis was performed 
using the parametric Welch two sample t-test and the nonparametric Kruskal-Wallis test. 
All relationships were nonsignificant at the α=.05 level with the most significant 
21 
 
relationship demonstrating a p value of 0.0685 for the correlation between headaches and 
beta blocker treatment (See Appendix E). A multiple linear regression model using a n 
response variable created by combining the hours spent vertical variable with the variable 
inactivity/function converted to a 24 hour scale showed no significant relationships in the 
data between any of the variables, but showed once again that headaches and pain were 
the most strongly influenced variables from the beta blockade with p values of 0.0982 
and 0.1020, respectively (See Appendix F). Further analysis was not warranted by the 
nonsignificant findings of this preliminary investigation. The demographic data for the 







3.1 Significance of Findings 
 Although no statistically significant findings presented themselves, some 
observations are worth discussion and further investigation. Twenty-five of the 55 
patients (46%) included in the study noted some improvement of symptoms when on 
propranolol or metoprolol. Fourteen of the 55 patients (25%) reported negative effects 
ranging from increased fatigue to suicidal ideations. Sixteen of the 55 patients (29%) did 
not report any effect either positive or negative. These data are presented visually in 
Figure 3. Although more patients appear to benefit from treatment, these data must be 
interpreted in the context of being recorded by the prescribing physician and the patients 
who want the treatment to work and are looking for any benefit and possibly 
downplaying any negative effects. Table 1 lists clinical notes on patient responses to 
propranolol or metoprolol treatment. The table shows tremor and POTS are frequently 
alleviated by beta blockade, whereas common side effects include gastrointestinal 
symptoms, increased fatigue, and tiredness. Some patients respond well while others 
display only negative effects. Some patients benefited, but also displayed side effects to 
the medications. These patients were classified as positive or negative responders based 










Figure 3. The relative percentages of patient responses to treatment  












Patient Response to Beta Blockers 









Patient’s subjective reporting of the effects of treatment with beta blockers. 
Positively responding patients Negatively responding patients 
1. feels less dizzy, heart rate increase less 
dramatic on challenge,  
2. saw improvement in trembling and severe 
illness,  
3. helps with tremor and anxiety,  
4. fewer lows,  
5. has added benefit, helped her to be up longer, 
improved function, 
6. more active, more energy, generally doing well,  
7. tremor and handwriting a bit improved, 
8. mild improvement attributed to propranolol, 
does notice a difference when taken,  
9. less dizzy, fewer headaches, helps POTS,  
10. effective for tremor, feels better, essential 
tremor much better, helps with OI and pain,  
11. headaches and resting pulse better, tolerates 
more activity,  
12. not making her tired, POTS seems better 
13. helpful for treating autonomic overload 
symptoms,  
14. better control of tachycardia,  
15. helpful to control OI,  
16. POTS and tachycardia better,  
17. helps with performance anxiety, better control 
of blood pressure,  
18. feeling better overall with more energy, 
19. improves tachycardia,  
20. pulse and blood pressure swings are less 
dramatic,  
21. less malaise and anxiety,  
22. more active, less depressed, 
23. helps POTS,  
24. increased activity,  
25. POTS better, 
1. caused fatigue, hot flashes 
and aches,  
2. caused bradycardia, 
dizziness and OI, 
3. caused bradycardia, causes 
headaches, nausea, and 
hypertonia arterialis,  
4. contributes to fatigue, 
caused nausea and 
vomiting,  
5. caused nocturnal diarrhea, 
6. increased sleepiness and 
fatigue,  
7. caused brain fog,  
8. multiple side effects,  
interfering with other 
medications, 
9. increased tiredness, too 
tired and depressed,  
10. allergic to propranolol,  
11. worsening depression with 
suicidal ideation,  
12. felt flat, tired, sleepy,  
13. autonomic symptoms 
worse, 




some patients while others displayed only positive responses gives more credence to the 
findings of other researchers that have shown possible genetic subtypes of ME/CFS that 
respond to beta-blockade treatment more favorably than others.
41,43
 
Figure 4 shows a comparison of gene expression in ME/CFS patients, one male and 
one female treated with propranolol as well as four age and gender matched controls. 
These data suggest that with more research, potential genetic subtypes of patients with 
ME/CFS could be identified that would respond favorably to specific treatments as well 
as those who should not be treated with them. Postulation aside, the current data show 
that nearly half of the patients selected for this study reported some beneficial effect of 
using low dose beta-blockers. This is a promising and exciting observation and although 
many limitations exist in the current study, further work should be performed to more 
thoroughly explore the effects of beta blockade on ME/CFS patients.  
 
3.2 Limitations and Future Work 
The study design investigating the effects of low dose beta-blockers on ME/CFS 
limited the potential outcome. The study population was selected retrospectively and 
variables with potential influence on the outcome were not controlled for. Some of these 
confounding variables may include subclassifying patients by gender or age, interfering 
medications or treatment modalities and dosing, reporting biases or misattribution of 
symptoms and side effects, and lack of uniform and clearly defined definitions of 
symptom reporting by patients. No subgroups were formed and no division of the data 
was made by age or gender. This division, if used in future studies, may help identify a 








Figure 4. A comparison of the activation of 13 genes in matched untreated    
and propranolol treated individuals after an exercise challenge.  







while others have been struggling with symptoms for decades. Some patients had up to 
12 different medications that could have contributed to the outcome in any number of 
unknown ways. Further control for variables such as these could have masked 
statistically significant results. With a carefully designed clinical trial for propranolol or 
other beta-blocker treatment of ME/CFS, significant results may be observed and patient 
care improved with its use. There may also be a subgroup of ME/CFS sufferers that have 
specific genetic profiles that can be isolated. Some genotypes may be more responsive to 
beta-blockade than other genotypes. Isolation of these genotypes could not only yield 
better treatment results, but may allow research protocols that have failed to find 
significance in the past to find useful results in the search for the ME/CFS root cause. 
Further studies should be designed with more control over variables and subclassifying 
patient populations.  
 
3.3 Conclusions 
ME/CFS is a serious condition that cripples the lives of people young and old every 
day. Even a slight improvement in functionality for these individuals could give them 
more productive and meaningful lives and benefit society. Research into methods to treat 
and improve the symptoms of this population should continue at a more rapid pace. There 
is much potential for improvement of our understanding of the pathophysiology of this 
disease and how to more effectively treat it. With more research, low dose beta-blockers 
may yet prove to be efficacious in reducing the symptom load of ME/CFS sufferers, but 
this treatment method will not be a cure. If a root cause or perhaps multiple causes are 




itself. Until that time, treatment modalities, such as beta-blockades, may allow ME/CFS 






















  Table 2 
 
Myalgic encephalomyelitis: international consensus criteria. 
Adult and paediatric, clinical and research 
 
Myalgic encephalomyelitis is an acquired neurological disease with complex global 
dysfunctions. Pathological dysregulation of the nervous, immune and endocrine systems, 
with impaired cellular energy metabolism and ion transport are prominent features. 
Although signs and symptoms are dynamically interactive and causally connected, the 
criteria are grouped by regions of pathophysiology to provide general focus. 
  
A patient will meet the criteria for postexertional neuroimmune exhaustion (A), at least 
one symptom from three neurological impairment categories (B), at least one symptom 
from three immune/gastro-intestinal/genitourinary impairment categories (C), and at 
least one symptom from energy metabolism/transport impairments (D). 
 
A. Postexertional neuroimmune exhaustion (PENE pen’-e): Compulsory 
 1. Marked, rapid physical and/or cognitive fatigability in response to exertion, which 
may be minimal such as activities of daily living or simple mental tasks, can be 
debilitating and cause a relapse. 
 
Operational notes: For a diagnosis of ME, symptom severity must result in a significant 
reduction of a patient’s premorbid activity level. Mild (an approximate 50% reduction in 
pre-illness activity level), moderate (mostly housebound), severe (mostly bedridden) or 
very severe (totally bedridden and need help with basic functions). There may be marked 
fluctuation of symptom severity and hierarchy from day to day or hour to hour. Consider 
activity, context and interactive effects. Recovery time: e.g. Regardless of a patient’s 
recovery time from reading for ½ hour, it will take much longer to recover from grocery 
shopping for ½ hour and even longer if repeated the next day – if able. Those who rest 
before an activity or have adjusted their activity level to their limited energy may have 
shorter recovery periods than those who do not pace their activities adequately. Impact: 
e.g. An outstanding athlete could have a 50% reduction in his/her pre-illness activity 





Table 2 continued 
Adult and paediatric, clinical and research 
 
B. Neurological impairments 
At least one symptom from three of the following four symptom categories 
 
1. Neurocognitive impairments 
 
  a. Difficulty processing information: slowed thought, impaired concentration e.g. 
confusion, disorientation, cognitive overload, difficulty with making decisions, slowed 
speech, acquired or exertional dyslexia 
  
 b. Short-term memory loss: e.g. difficulty remembering what one wanted to say, what 




a. Headaches: e.g. chronic, generalized headaches often involve aching of the eyes, 
behind the eyes or back of the head that may be associated with cervical muscle tension; 
migraine; tension headaches 
 
  b. Significant pain can be experienced in muscles, muscle-tendon junctions, joints, 
abdomen or chest. It is noninflammatory in nature and often migrates. E.g. generalized 
hyperalgesia, widespread pain (may meet fibromyalgia criteria), myofascial or radiating 
pain 
 
 3. Sleep disturbance 
 a. Disturbed sleep patterns: e.g. insomnia, prolonged sleep including naps, sleeping 
most of the day and being awake most of the night, frequent awakenings, awaking much 
earlier than before illness onset, vivid dreams/nightmares 
   





Table 2 continued 
Adult and paediatric, clinical and research 
 
 b. Motor: e.g. muscle weakness, twitching, poor coordination, feeling unsteady on feet, 
ataxia 
 
Notes: Neurocognitive impairments, reported or observed, become more pronounced 
with fatigue.Overload phenomenamay be evident when two tasks are performed 
simultaneously. Abnormal accommodation responses of the pupils are common. Sleep 
disturbancesare typically expressed by prolonged sleep, sometimes extreme, in the acute 
phase and often evolve into marked sleep reversal in the chronic stage. Motor 
disturbances may not be evident in mild or moderate cases but abnormal tandem gait and 
positive Romberg test may be observed in severe cases. 
 
C. Immune, gastro-intestinal and genitourinary impairments 
At least one symptom from three of the following five symptom categories 
  
1. Flu-like symptoms may be recurrent or chronic and typically activate or worsen with 
exertion. e.g. sore throat, sinusitis, cervical and/or axillary lymph nodes may enlarge or 
be tender on palpitation 
  
2. Susceptibility to viral infections with prolonged recovery periods 
  
3. Gastro-intestinal tract: e.g. nausea, abdominal pain, bloating, irritable bowel 
syndrome 
  
4. Genitourinary: e.g. urinary urgency or frequency, nocturia 
  
5. Sensitivities to food, medications, odours or chemicals 
  
Notes: Sore throat, tender lymph nodes, and flu-like symptoms obviously are not specific 
to ME but their activation in reaction to exertion is abnormal. The throat may feel sore,  
dry and scratchy. Faucial injection and crimson crescents may be seen in the tonsillar 




Table 2 continued 
Adult and paediatric, clinical and research 
 
D. Energy production/transportation impairments: At least one symptom 
  
1. Cardiovascular: e.g. inability to tolerate an upright position - orthostatic intolerance, 
neurally mediated hypotension, postural orthostatic tachycardia syndrome, palpitations 
with or without cardiac arrhythmias, light-headedness/dizziness 
 
2. Respiratory: e.g. air hunger, laboured breathing, fatigue of chest wall muscles 
  
3. Loss of thermostatic stability: e.g. subnormal body temperature, marked diurnal 
fluctuations; sweating episodes, recurrent feelings of feverishness with or without low 
grade fever, cold extremities 
  
4. Intolerance of extremes of temperature 
 
Notes: Orthostatic intolerance may be delayed by several minutes. Patients who have 
orthostatic intolerance may exhibit mottling of extremities, extreme pallor or Raynaud’s 
Phenomenon. In the chronic phase, moons of finger nails may recede. 
 
Paediatric considerations 
Symptoms may progress more slowly in children than in teenagers or adults. In addition 
to postexertional neuroimmune exhaustion, the most prominent symptoms tend to be 
neurological: headaches, cognitive impairments, and sleep disturbances. 
  
1. Headaches: Severe or chronic headaches are often debilitating. Migraine may be 
accompanied by a rapid drop in temperature, shaking, vomiting, diarrhoea and severe 
weakness. 
 
2. Neurocognitive impairments: Difficulty focusing eyes and reading are common. 
Children may become dyslexic, which may only be evident when fatigued. Slow 






Table 2 continued 
Adult and paediatric, clinical and research 
 
All cognitive impairments worsen with physical or mental exertion. Young people will 
not be able to maintain a full school programme. 
 
3. Pain may seem erratic and migrate quickly. Joint hypermobility is common. 
 
Notes: Fluctuation and severity hierarchy of numerous prominent symptoms tend to vary 
more rapidly and dramatically than in adults. 
 
Classification 
——— Myalgic encephalomyelitis 
——— Atypical myalgic encephalomyelitis: meets criteria for postexertional 
neuroimmune exhaustion but has a limit of two less than required of the remaining 
criterial symptoms. Pain or sleep disturbance may be absent in rare cases. 
 
Exclusions: As in all diagnoses, exclusion of alternate explanatory diagnoses is achieved 
by the patient’s history, physical examination, and laboratory/biomarker testing as  
indicated. It is possible to have more than one disease but it is important that each one is  
identified and treated. Primary psychiatric disorders, somatoform disorder and substance 
abuse are excluded. Paediatric:‘primary’ school phobia. 
Comorbid entities: Fibromyalgia, myofascial pain syndrome, temporomandibular joint 
syndrome, irritable bowel syndrome, interstitial cystitis, Raynaud’s phenomenon, 
prolapsed mitral valve, migraines, allergies, multiple chemical sensitivities, Hashimoto’s 
thyroiditis, Sicca syndrome, reactive depression. Migraine and irritable bowel syndrome 

































































































































Figure 19. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 20. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 21. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 22. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 23. Scatterplot comparing brain fog before and after propranolol treatment to body 





Figure 24. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 25. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 26. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 27. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 28. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 29. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 30. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 31. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 32. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 33. Scatterplot comparing depression/anxiety before and after propranolol 





Figure 34. Scatterplot comparing fatigue before and after propranolol treatment to 





Figure 35. Scatterplot comparing fatigue before and after propranolol treatment to body 





Figure 36. Scatterplot comparing fatigue before and after propranolol treatment to brain 





Figure 37. Scatterplot comparing fatigue before and after propranolol treatment to 





Figure 38. Scatterplot comparing fatigue before and after propranolol treatment to 





Figure 39. Scatterplot comparing fatigue before and after propranolol treatment to hours 





Figure 40. Scatterplot comparing fatigue before and after propranolol treatment to hours 





Figure 41. Scatterplot comparing fatigue before and after propranolol treatment to 





Figure 42. Scatterplot comparing fatigue before and after propranolol treatment to pain 





Figure 43. Scatterplot comparing fatigue before and after propranolol treatment to pain 





Figure 44. Scatterplot comparing fatigue before and after propranolol treatment to sleep 





Figure 45. Scatterplot comparing brain fog before and after propranolol treatment to 





Figure 46. Scatterplot comparing brain fog before and after propranolol treatment to 





Figure 47. Scatterplot comparing brain fog before and after propranolol treatment to 





Figure 48. Scatterplot comparing brain fog before and after propranolol treatment to pain 





Figure 49. Scatterplot comparing brain fog before and after propranolol treatment to 





Figure 50. Scatterplot comparing brain fog before and after propranolol treatment to sleep 





Figure 51. Scatterplot comparing brain fog before and after propranolol treatment to 





Figure 52. Scatterplot comparing headaches before and after propranolol treatment to 





Figure 53. Scatterplot comparing brain fog before and after propranolol treatment to pain 





Figure 54. Scatterplot comparing headaches before and after propranolol treatment to 





Figure 55. Scatterplot comparing headaches before and after propranolol treatment to 





Figure 56. Scatterplot comparing headaches before and after propranolol treatment to 





Figure 57. Scatterplot comparing headaches before and after propranolol treatment to 





Figure 58. Scatterplot comparing inactivity/function before and after propranolol 





Figure 59. Scatterplot comparing pain before and after propranolol treatment to activity 





Figure 60. Scatterplot comparing pain before and after propranolol treatment to 





Figure 61. Scatterplot comparing pain before and after propranolol treatment to hours 





Figure 62. Scatterplot comparing pain before and after propranolol treatment to 





Figure 63. Scatterplot comparing pain before and after propranolol treatment to sleep 





Figure 64. Scatterplot comparing pain before and after propranolol treatment to pain sum 





Figure 65. Scatterplot comparing sleep problems before and after propranolol treatment 





Figure 66. Scatterplot comparing sleep problems before and after propranolol treatment 





Figure 67. Scatterplot comparing pain before and after propranolol treatment to hours 





Figure 68. Scatterplot comparing sleep problems before and after propranolol treatment 





Figure 69. Scatterplot comparing sleep problems before and after propranolol treatment 





Figure 70. Scatterplot comparing pain sum before and after propranolol treatment to 





Figure 71. Scatterplot comparing pain sum before and after propranolol treatment to 





Figure 72. Scatterplot comparing pain sum before and after propranolol treatment to 





Figure 73. Scatterplot comparing pain sum before and after propranolol treatment to sleep 





Figure 74. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 75. Scatterplot comparing body aches before and after propranolol treatment to 





Figure 76. Scatterplot comparing body aches before and after propranolol treatment to 














ANALYSIS BETWEEN VARIABLES  





 Table 3 
 
Parametric and nonparametric statistical tests for significance of each variable. 
 
t-score                           degrees of freedom                         p-value 
Fatigue by Before.After.Propranolol 
t = -0.2235,   df = 152.502,   p-value = 0.8235 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -0.6408787  0.5106266 
sample estimates: 
 mean in group After mean in group Before  
            7.470588             7.535714 
Kruskal-Wallis  
chi-squared = 0.0086,  df = 1,   p-value = 0.9259 
  
 
Depress.Anxiety by Before.After.Propranolol 
t = -0.3757,   df = 152.646,   p-value = 0.7076 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.1143642  0.7582181 
sample estimates: 
 mean in group After mean in group Before  
            4.779070             4.957143 
Kruskal-Wallis  
chi-squared = 0.1591,  df = 1,    p-value = 0.69 
 
 
Brain.Fog by Before.After.Propranolol 
t = -0.5154,  df = 151.603,    p-value = 0.607 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -0.9057359  0.5309460 
sample estimates: 
 mean in group After mean in group Before  
            6.341176             6.528571  
Kruskal-Wallis  









Table 3 Continued 
 
t-score                           degrees of freedom                         p-value 
Body.Aches by Before.After.Propranolol 
t = -0.7947,   df = 148.496,   p-value = 0.428 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.189014  0.506941 
sample estimates: 
 mean in group After mean in group Before  
            5.886905             6.227941 
Kruskal-Wallis  
chi-squared = 0.3565,  df = 1,    p-value = 0.5505 
  
 
Pain by Before.After.Propranolol 
t = -1.2264,  df = 142.275,   p-value = 0.2221 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.4983764  0.3510178 
sample estimates: 
 mean in group After mean in group Before  
            5.349398             5.923077  
Kruskal-Wallis  
chi-squared = 1.3155,  df = 1,   p-value = 0.2514 
 
 
Pain.Sum by Before.After.Propranolol 
t = -0.8385,  df = 148.95,    p-value = 0.4031 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -2.4069919  0.9728182 
sample estimates: 
 mean in group After mean in group Before  
            11.17262             11.88971 
Kruskal-Wallis  












Table 3 Continued 
 
t-score                            degrees of freedom                       p-value 
Sleep.Problems by Before.After.Propranolol 
t = -1.0838,  df = 148.312,   p-value = 0.2802 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.4264530  0.4159488 
sample estimates: 
 mean in group After mean in group Before  
            5.553571             6.058824 
Kruskal-Wallis  
chi-squared = 0.8258,  df = 1,    p-value = 0.3635 
 
 
Inactivity.Function by Before.After.Propranolol 
t = -0.2772,   df = 36.058,    p-value = 0.7832 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.674050  1.271486 
sample estimates: 
 mean in group After mean in group Before  
            5.865385             6.066667 
Kruskal-Wallis  
chi-squared = 0.0365,  df = 1,    p-value = 0.8485 
 
 
Converted.to.24.scale by Before.After.Propranolol 
t = -0.2772,  df = 36.058,    p-value = 0.7832 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -2.845884  2.161525 
sample estimates: 
 mean in group After mean in group Before  
            9.971154            10.313333 
Kruskal-Wallis  












Table 3 Continued 
 
t-score                            degrees of freedom                       p-value 
Hours.Vert by Before.After.Propranolol 
t = -0.1179,   df = 100.135,   p-value = 0.9064 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.868625  1.659024 
sample estimates: 
 mean in group After mean in group Before  
             8.12069              8.22549 
Kruskal-Wallis  
chi-squared = 0.0037,  df = 1,   p-value = 0.9515 
 
 
Hours.Horiz by Before.After.Propranolol 
t = -0.1662,  df = 101.179,   p-value = 0.8683 
alternative hypothesis: true difference in means is not equal to 0 
95 percent confidence interval: 
 -1.928359  1.630185 
sample estimates: 
 mean in group After mean in group Before  
            15.58621             15.73529  
Kruskal-Wallis  























Multiple linear regression model. 
 
 
Regression model using the response variable of inactivity function converted to a 24      
hour scale combined with hours spent vertical 
Residuals: 
    Min      1Q  Median      3Q     Max  





                                  Estimate      Std. Error     t value    Pr(>|t|)     
(Intercept)                      12.37487    1.70976        7.238       3.36e-11 *** 
Before.After.PropranololBefore         -0.12265     0.78877        -0.156     0.8767     
Fatigue                          -0.15188     0.26108      -0.582      0.5617     
Depress.Anxiety                 -0.22850     0.18348        -1.245      0.2152     
Brain.Fog                        -0.21206     0.23114        -0.917      0.3606     
Body.Aches                        0.17733       0.29737        0.596       0.5520     
Pain                              -0.47863      0.29063       -1.647      0.1020     
Headaches                         0.30955       0.18589        1.665       0.0982 .   
Sleep.Problems                   -0.01549     0.17320       -0.089      0.9289     
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 4.556 on 132 degrees of freedom 
  (15 observations deleted due to missingness) 
Multiple R-squared:  0.1029,   Adjusted R-squared:  0.04848  


















Females (N) 43 
Males (N) 12 
Age mean (years) 39 
Age range (years) 15 - 76 
Mean Propranolol Dose (mg/day) 46 
Propranolol Dose Range (mg/day) 12.5 - 180 
Mean duration of Propranolol Treatment 
(Months) 
25 
Mean Height (cm) 65.8 
Mean Weight (lbs) 149.3 
Race 




     NSAIDs 
     Antidepressants 
     Sleep Aids 
     Benzodiazepines 
     Opioids 
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